Who are EU-approved RoActemra's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): tocilizumab [RoActemra/Actemra], Tocilizumab(400mg), CT-P47 PFS (tocilizumab), Actemra +MTX.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/eu-approved-roactemra.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

EU-approved RoActemra — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

EU-approved RoActemra (EU-approved RoActemra) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IL-6 receptor antagonist (monoclonal antibody). Area: Immunology.

phase 3 IL-6 receptor antagonist (monoclonal antibody) IL-6R (Interleukin-6 receptor) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

EU-approved RoActemra (EU-approved RoActemra) — Fresenius Kabi SwissBioSim GmbH. RoActemra (tocilizumab) is a humanized monoclonal antibody that blocks the interleukin-6 (IL-6) receptor, reducing inflammatory signaling in immune-mediated diseases.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
EU-approved RoActemra TARGET	EU-approved RoActemra	Fresenius Kabi SwissBioSim GmbH	phase 3	IL-6 receptor antagonist (monoclonal antibody)	IL-6R (Interleukin-6 receptor)
tocilizumab [RoActemra/Actemra]	tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche	marketed	IL-6 receptor antagonist (monoclonal antibody)	IL-6 receptor (IL-6R)
Tocilizumab(400mg)	Tocilizumab(400mg)	Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University	marketed	IL-6 receptor antagonist (monoclonal antibody)	IL-6 receptor (IL-6R)
CT-P47 PFS (tocilizumab)	CT-P47 PFS (tocilizumab)	Celltrion	phase 3	IL-6 receptor antagonist (monoclonal antibody)	IL-6 receptor (IL-6R)
Actemra +MTX	Actemra +MTX	Zhejiang Hisun Pharmaceutical Co. Ltd.	phase 3	IL-6 receptor antagonist (monoclonal antibody)	IL-6 receptor (IL-6R)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IL-6 receptor antagonist (monoclonal antibody) class)

Celltrion · 1 drug in this class
Fresenius Kabi SwissBioSim GmbH · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · 1 drug in this class
Zhejiang Hisun Pharmaceutical Co. Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). EU-approved RoActemra — Competitive Intelligence Brief. https://druglandscape.com/ci/eu-approved-roactemra. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing